Dr. Guryanova’s research is focused on the blood system, with a specific interest in hematologic malignancies. The overarching goal of her laboratory is to delineate the mechanisms of the cross-talk between epigenetics and chromatin organization, and how these processes contribute to the development of acute myeloid leukemia (AML), resistance to therapies, and clonal evolution. Ultimately, she would like to harness this mechanistic understanding to develop improved therapeutic approaches for leukemia.